Skip to main content
. 2022 Jun 2;17(6):e0269115. doi: 10.1371/journal.pone.0269115

Fig 2. The efficacy of each agent and three groups.

Fig 2

Kaplan-Meier plots of the (A) progression-free survival (PFS) after precedent and subsequent regorafenib therapy; (B) PFS after precedent and subsequent TFTD therapy; (C) PFS after sequential treatment with the two drugs (T-PFS); (D) overall survival (OS).